Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Karnon

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|April 17, 2003
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patientsJon Karnon, Trefor Jones
Australian Journal of Primary Health|November 25, 2011
An equity-effectiveness framework linking health programs and healthy life expectancyDavid Banham, John Lynch, Jon Karnon
Pharmacoeconomics|July 16, 2010
The value of value of information: best informing research design and prioritization using current methodsSimon Eckermann, Jon Karnon, Andrew R Willan
Breast Cancer Research and Treatment|July 6, 2006
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancerKhalid El Ouagari, Jon Karnon, Thomas Delea, et al.
BMJ Open|December 26, 2019
Supporting surgeons in patient-centred complex decision-making: a qualitative analysis of the impact of a perioperative physician clinicClarabelle T Pham, Catherine L Gibb, Robert A Fitridge, et al.
The Australian Journal of Rural Health|May 19, 2025
A Cost Comparison From a Health Service Perspective of Three Allied Health Models of Care for Remote Australia: Student-Assisted Services, Fly-In Fly-Out Services and Services Provided by a Resident ClinicianNarelle Campbell, Jackie Roseleur, Jon Karnon, et al.
Clinical Breast Cancer|June 27, 2007
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancerThomas E Delea, Jon Karnon, Oleg Sofrygin, et al.
Pharmacoeconomics|October 7, 2009
Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamidePeng Liubao, Wan Xiaomin, Tan Chongqing, et al.
Current Medical Research and Opinion|May 11, 2005
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UKJon Karnon, Alan Brennan, Abdullah Pandor, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 25, 2011
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumabThomas E Delea, Paul Tappenden, Oleg Sofrygin, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|April 17, 2003
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patientsJon Karnon, Trefor Jones
Australian Journal of Primary Health|November 25, 2011
An equity-effectiveness framework linking health programs and healthy life expectancyDavid Banham, John Lynch, Jon Karnon
Pharmacoeconomics|July 16, 2010
The value of value of information: best informing research design and prioritization using current methodsSimon Eckermann, Jon Karnon, Andrew R Willan
Breast Cancer Research and Treatment|July 6, 2006
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancerKhalid El Ouagari, Jon Karnon, Thomas Delea, et al.
BMJ Open|December 26, 2019
Supporting surgeons in patient-centred complex decision-making: a qualitative analysis of the impact of a perioperative physician clinicClarabelle T Pham, Catherine L Gibb, Robert A Fitridge, et al.
The Australian Journal of Rural Health|May 19, 2025
A Cost Comparison From a Health Service Perspective of Three Allied Health Models of Care for Remote Australia: Student-Assisted Services, Fly-In Fly-Out Services and Services Provided by a Resident ClinicianNarelle Campbell, Jackie Roseleur, Jon Karnon, et al.
Clinical Breast Cancer|June 27, 2007
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancerThomas E Delea, Jon Karnon, Oleg Sofrygin, et al.
Pharmacoeconomics|October 7, 2009
Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamidePeng Liubao, Wan Xiaomin, Tan Chongqing, et al.
Current Medical Research and Opinion|May 11, 2005
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UKJon Karnon, Alan Brennan, Abdullah Pandor, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 25, 2011
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumabThomas E Delea, Paul Tappenden, Oleg Sofrygin, et al.
Pageof 2